Skip to main
BFRI
BFRI logo

Biofrontera (BFRI) Stock Forecast & Price Target

Biofrontera (BFRI) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biofrontera Inc is poised for significant revenue growth due to the anticipated launch of new treatment indications for superficial Basal Cell Carcinoma and Actinic Keratoses in 2026 and 2027. The company's strategy of expanding its sales force, combined with favorable reimbursement policies that enhance Ameluz's market position over traditional cryotherapy, is expected to attract new customers to its photodynamic therapy offerings. Additionally, historical sales trends indicate that the fourth quarter will be crucial for revenue performance, especially with the recent update that allows increased dosing of Ameluz per treatment, potentially leading to higher sales volumes.

Bears say

Biofrontera Inc faces a negative outlook primarily due to its reported revenue of $8.6 million, which fell short of both estimates of $10.6 million and consensus predictions. Furthermore, the potential for regulatory surprises poses significant risks that could adversely affect revenue generation while also increasing operational costs. Lastly, the company's stock price is projected to decrease significantly, with expectations to align closer to a comp group average of 3x 2026 revenue, indicating concerns over its growth and execution capabilities.

Biofrontera (BFRI) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biofrontera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biofrontera (BFRI) Forecast

Analysts have given Biofrontera (BFRI) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Biofrontera (BFRI) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biofrontera (BFRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.